OxyPrem develops a non-invasive oxygen sensor that continuously monitors brain oxygen levels in high-risk preterm infants using reusable high-precision sensors and advanced algorithms. This technology provides real-time data to medical teams, enabling timely interventions to prevent permanent brain damage due to inadequate oxygenation.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inadequate oxygenation in preterm infants can lead to permanent brain damage, but current monitoring methods are often invasive or lack the precision needed for timely intervention. Continuous, non-invasive monitoring of brain oxygen levels is crucial for preventing long-term neurological consequences in this vulnerable population.
Solution
OxyPrem has developed a non-invasive oxygen sensor designed to continuously monitor brain oxygen levels in high-risk preterm infants. The system utilizes reusable, high-precision sensors and advanced algorithms to provide real-time data to medical teams. This enables timely interventions to prevent permanent brain damage resulting from inadequate oxygenation. The technology aims to address the critical need for precise and continuous monitoring in neonates, allowing for proactive management of oxygen levels and improved outcomes.
Target Audience
The primary target audience includes neonatologists, neonatal intensive care units (NICUs), and hospitals caring for preterm infants.
Features
- Reusable, high-precision sensors designed for the smallest patients
- Advanced algorithms for accurate brain oxygen monitoring
- Non-invasive technology for continuous monitoring
- Real-time data delivery to medical teams